Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting

May 9, 2024

https://www.globenewswire.com/news-release/2024/05/09/2878571/0/en/Generation-Bio-Announces-the-Presentation-of-Preclinical-Data-on-iqDNA-and-ctLNP-Platforms-at-the-ASGCT-27th-Annual-Meeting.html

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) —  Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms as well as its enzymatic synthesis manufacturing at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting. A sixth presentation on the company’s ctLNP platform will be discussed in an oral presentation on Saturday, May 11.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.